Date:-05.06.2024
To,
The Manager
Listing Department
BSE Limited
Phiroze Jeejeebhoy Towers Dalal Street, Mumbai - 400 001

SCRIP CODE: 541096

Sub: Acquisition of additional Equity shares of Varenyam Healthcare Pvt Ltd
Ref: Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir/Madam,

Pursuant to Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulation"), we hereby inform you that Bharat Parenterals Ltd ("the Company") will acquire additional 2,50,000 Equity shares of Rs.10 each of Varenyam Healthcare Pvt Ltd, being held by Mr. Bharat Desai (100), Himaben Bharatkumar Desai (1,27,449), Shahim Bharatkumar Desai (62,475) and Nikita Shahim Desai (59,976) and as consideration will issue 346318 Equity Shares on preferential basis subject to necessary approval.

The details as required under Regulation 30 of the SEBI Listing Regulation read with SEBI Circular no. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated 23.07.2023 are as under:

| a) Name of the target entity, details in brief such as size, turnover etc. | Varenyam Healthcare Pvt Ltd ("VHPL")  
  Authorised capital: 10,00,000 equity shares of Rs.10 each aggregating to 1,00,00,000/-  
  Paid up capital: 2,50,000 equity shares of Rs.10 each aggregating to Rs. 25,00,000/-  
  Turnover for the year ended March 31, 2024 (Fig Rs. In Lakhs): Rs. 4872.28/- |
|--------------------------------------------------|-----------------------------------------|
| b) whether the acquisition would fall within related party transaction(s) and whether the promoter/promoter group/group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length"; | Yes, Equity Shares held by Mr. Bharat Desai (100), Himaben Bharatkumar Desai (1,27,449), Bham Bharatkumar Desai (62,475) and Nikita Bham Desai (59,976) will be transferred in favor of M/s. Bharat Parenterals Ltd.  
  Hence transfer of shares is between related parties. The said Related Party Transactions was approved by the Audit Committee and Board of Directors at their meeting held on 05th June 2024 and will be executed only after approval of Shareholders. |


<table>
<thead>
<tr>
<th><strong>c) industry to which the entity being acquired belongs</strong></th>
<th>Promoter / promoter group are interested in the above transaction.</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>d) objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)</strong></td>
<td>Pursuant to proposed acquisition, the company become wholly Owned Subsidiary (WOS) Company so that the company will have better control over and run the business in a manner required. The business of the Company is not outside the main line of business of the listed entity.</td>
</tr>
<tr>
<td><strong>e) brief details of any governmental or regulatory approvals required for the acquisition</strong></td>
<td>Not applicable</td>
</tr>
<tr>
<td><strong>f) indicative time period for completion of the acquisition</strong></td>
<td>By June 30th, 2024 subject to approval of shareholders</td>
</tr>
<tr>
<td><strong>g) nature of consideration - whether cash consideration or share swap and details of the same</strong></td>
<td>As a part of consideration, the company will be issuing its own shares to the shareholders of Varenyam Healthcare Pvt Ltd against purchase of these shares, subject to necessary approval and valuation report i.e. Share Swap. The exchange ratio is based on the valuation report received from Independent Valuer.</td>
</tr>
<tr>
<td><strong>h) cost of acquisition or the price at which the shares are acquired</strong></td>
<td>250000 Equity shares held by various shareholders as mentioned above in Varenyam Healthcare Private Limited will be acquired by the company by issuing 346318 Equity Shares of Rs. 10 with a premium of Rs. 1491 per shares subject to closing adjustment.</td>
</tr>
<tr>
<td><strong>i) percentage of shareholding/control acquired and /or number of shares acquired</strong></td>
<td>Earlier the Company was holding 0% in Varenyam Healthcare Pvt Ltd. After the proposed acquisition, the Company will holds 100% equity shares in Varenyam Healthcare Pvt Ltd. As a result will become Wholly Owned Subsidiary of the Company. Acquisition of such shares shall be subject to the approval of shareholders and other approvals.</td>
</tr>
<tr>
<td><strong>j) brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief)</strong></td>
<td>Varenyam Healthcare Pvt Ltd engaged in the business of Marketing of pharmaceuticals products in India with help of Sales Team. Date of incorporation: 19.07.2016 Last three years’ turnover: [below Fig. in Lakhs] 2021-22: 5439.69 2022-23: 3552.97 2023-24: 4872.28 Country of presence: India</td>
</tr>
</tbody>
</table>
Kindly acknowledge the receipt and inform the members of the Exchanges.

Thank you,

For, Bharat Parenterals Limited

Krutika Bhattbhatt
Company Secretary & Compliance officer
M.No.F11482